nach oben

Erschienen in:

01.05.2023 | Case report

Ipilimumab/nivolumab/nivolumab/pembrolizumab

Type 1 diabetes: case report

Einloggen, um Zugang zu erhalten

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

…

Kawata S, et al. Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients. Diabetes 72 : 511-519, No. 4, Apr 2023. Available from: URL: https://diabetesjournals.org/diabetes/article/72/4/511/148304/Inflammatory-Cell-Infiltration-Into-Islets-Without

Titel: Ipilimumab/nivolumab/nivolumab/pembrolizumab
Type 1 diabetes: case report
Publikationsdatum: 01.05.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-38899-3